Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

SELUTION 4 De Novo Small Vessel IDE Trial

21 september 2026 uppdaterad av: M.A. Med Alliance S.A.

En prospektiv randomiserad enkelblind multicenterstudie för att bedöma säkerheten och effektiviteten hos SELUTION SLR™ 014 PTCA-läkemedelseluerande ballong vid behandling av patienter med De Novo kranskärlsskador i små kärl

Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA.

The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a parallel pharmacokinetic (pK) substudy, at up to 80 sites in the US, Canada, Brazil, Japan and Europe. A minimum of 50% of the subjects will be enrolled in the US.

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Detaljerad beskrivning

Prospective, randomized controlled, single-blind, multicenter, clinical trial

The study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a parallel pharmacokinetic (pK) substudy, at up to 80 sites in the US, Canada, Brazil, Japan and Europe. A minimum of 50% of the subjects will be enrolled in the US.

Subjects who present with chronic coronary syndrome (CCS), unstable angina or stabilized non-ST elevation myocardial infarction (NSTEMI) with an indication for percutaneous coronary intervention (PCI) with planned intervention for de novo lesions in small coronary vessels (RVD 2.00 mm to 2.75 mm) and meeting all eligibility criteria will be randomized 1:1 to treatment of the identified target lesion with either the SELUTION SLR 014 PTCA DEB or contemporary DES.

Randomized Cohort:

  • Intervention (DEB Strategy): Subjects randomized to the SELUTION SLR 014 PTCA DEB arm will receive lesion preparation according to the 3rd drug coated balloon (DCB) consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, intravascular lithotripsy, laser, rotational or orbital atherectomy, cutting or scoring balloon at the discretion of the operator as needed to reduce diameter stenosis to ≤ 30%). Subjects with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis > 30%) will receive a DES instead of the SELUTION DEB but remain in the SELUTION DEB group (intention to treat analysis). The DEB should not be used after DES implant.
  • Control (DES): Subjects randomized to the DES arm will receive treatment using any FDA approved "limus-based" DES, as per standard institutional practice.

Angiographic Substudy:

The angiographic substudy is a parallel registry consisting of up to 30 additional consecutive subjects meeting all eligibility criteria treated with the SELUTION DEB recruited at select study sites. These subjects will undergo angiography at 12 months post-procedure. Clinical follow-up will not extend beyond 12 months in this cohort.

Pharmacokinetic (pK) Substudy:

The pKsubstudy is a parallel registry consisting of up to 20 additional consecutive subjects meeting all eligibility criteria treated with the SELUTION DEB recruited at select study sites. This study will be conducted under an approved substudy protocol and will include blood draws at regular intervals to characterize the pK plasma profile of sirolimus.

Primary Endpoint:

Target lesion failure (TLF), defined as the composite of cardiac death, target-vessel myocardial infarction (MI) or clinically-driven target lesion revascularization (TLR) at 12 months. MI includes spontaneous (Type 1) MI using the 4th Universal Definition of Myocardial Infarction (UDMI) and peri-procedural MI using the Society for Cardiac Angiography and Intervention (SCAI) definition.

Studietyp

Interventionell

Inskrivning (Beräknad)

960

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Genk, Belgien, 3600
        • ZOL Genk
      • Hasselt, Belgien, 3500
        • Hartcentrum Hasselt Jessa Ziekenhuis
    • Arkansas
      • Jonesboro, Arkansas, Förenta staterna, 72401
        • St. Bernards
    • California
      • Chula Vista, California, Förenta staterna, 91911
        • CISD Sharp Chula Vista
      • Los Angeles, California, Förenta staterna, 90048
        • Cedars Sinai
      • Thousand Oaks, California, Förenta staterna, 91360
        • HCA Los Robles
      • Torrance, California, Förenta staterna, 90502
        • Harbor UCLA
    • Colorado
      • Golden, Colorado, Förenta staterna, 80401
        • Colorado Heart and Vascular
      • Thornton, Colorado, Förenta staterna, 80023
        • ClinRe
    • Connecticut
      • New Haven, Connecticut, Förenta staterna, 06520
        • Yale New Haven Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, Förenta staterna, 20010
        • MedStar Washington Hospital Center
    • Florida
      • Bradenton, Florida, Förenta staterna, 34208
        • Manatee Memorial
      • Clearwater, Florida, Förenta staterna, 34695
        • Mease Countryside Hospital
      • Jacksonville, Florida, Förenta staterna, 32209
        • University of Florida, Jacksonville
      • Largo, Florida, Förenta staterna, 33770
        • HCA Largo
      • Orlando, Florida, Förenta staterna, 32803
        • AdventHealth Orlando
      • St. Petersburg, Florida, Förenta staterna, 33709
        • HCA Northside
      • Trinity, Florida, Förenta staterna, 34655
        • HCA Trinity
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30309
        • Piedmont Heart Institute
      • Atlanta, Georgia, Förenta staterna, 30033
        • Atlanta VA
      • Atlanta, Georgia, Förenta staterna, 30322
        • Emory
      • Dalton, Georgia, Förenta staterna, 30720
        • Hamilton Medical Center
      • Thomasville, Georgia, Förenta staterna, 31792
        • Archbold Memorial Hospital
    • Hawaii
      • ‘Aiea, Hawaii, Förenta staterna, 96701
        • Pali Momi Medical Center
    • Illinois
      • Downers Grove, Illinois, Förenta staterna, 60515
        • Advocate Good Samaritan Hospital
      • Oak Lawn, Illinois, Förenta staterna, 60453
        • Advocate Christ Medical Center
      • Urbana, Illinois, Förenta staterna, 61801
        • Carle Foundation Hospital
    • Iowa
      • Iowa City, Iowa, Förenta staterna, 52242
        • University of Iowa Medical Center
    • Kansas
      • Wichita, Kansas, Förenta staterna, 67226
        • Cardiovascular Research Institute of Kansas
    • Kentucky
      • Lexington, Kentucky, Förenta staterna, 40503
        • Baptist Health Lexington
    • Louisiana
      • Houma, Louisiana, Förenta staterna, 70360
        • Cardiovascular Institute of the South
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21201
        • University of Maryland
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02115
        • Brigham & Women's
      • Boston, Massachusetts, Förenta staterna, 02114
        • Mass General
      • Boston, Massachusetts, Förenta staterna, 02114
        • Beth Israel Deaconess
      • Springfield, Massachusetts, Förenta staterna, 01199
        • Baystate Medical Center
    • Minnesota
      • Minneapolis, Minnesota, Förenta staterna, 55417
        • Minneapolis VA Medical Center
      • Minneapolis, Minnesota, Förenta staterna, 55407
        • Minneapolis Heart Institute
    • Mississippi
      • Tupelo, Mississippi, Förenta staterna, 38801
        • North Mississippi Medical Center
    • Missouri
      • Overland Park, Missouri, Förenta staterna, 66211
        • HCA Overland Park
      • St Louis, Missouri, Förenta staterna, 63136
        • St. Louis Heart and Vascular
    • Nebraska
      • Omaha, Nebraska, Förenta staterna, 68198
        • University of Nebraska
    • New Jersey
      • Englewood, New Jersey, Förenta staterna, 07631
        • Englewood Health
    • New York
      • New York, New York, Förenta staterna, 10029
        • Icahn School of Medicine at Mount Sinai
      • New York, New York, Förenta staterna, 10075
        • Northwell Health Lenox Hill
      • Stony Brook, New York, Förenta staterna, 11794
        • Stony Brook University Hospital
    • North Carolina
      • Raleigh, North Carolina, Förenta staterna, 27607
        • NC Heart and Vascular
    • Ohio
      • Cincinnati, Ohio, Förenta staterna, 45219
        • The Lindner Research Center at Christ
      • Cleveland, Ohio, Förenta staterna, 44120
        • UH Cleveland
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73120
        • Oklahoma Heart
    • Pennsylvania
      • Hershey, Pennsylvania, Förenta staterna, 17033
        • Penn State Health Hershey & Berks
      • Mechanicsburg, Pennsylvania, Förenta staterna, 17050
        • UPMC Pinnacle
      • York, Pennsylvania, Förenta staterna, 17403
        • WellSpan York Hospital
    • Rhode Island
      • Providence, Rhode Island, Förenta staterna, 02903
        • Lifespan Rhode Island & Miriam
    • Tennessee
      • Chattanooga, Tennessee, Förenta staterna, 37404
        • CHI Memorial
      • Chattanooga, Tennessee, Förenta staterna, 37404
        • University of Nebraska
      • Nashville, Tennessee, Förenta staterna, 37203
        • HCA Centennial
    • Texas
      • Abilene, Texas, Förenta staterna, 79601
        • Hendrick Health
      • Dallas, Texas, Förenta staterna, 75231
        • Texas Health
      • Dallas, Texas, Förenta staterna, 75246
        • Baylor Scott and White - Dallas
      • Fort Worth, Texas, Förenta staterna, 76104
        • Medical City of Fort Worth
      • Plano, Texas, Förenta staterna, 75093
        • Baylor Scott and White Plano
      • Temple, Texas, Förenta staterna, 76508
        • Baylor Scott and White - Temple
    • Utah
      • Murray, Utah, Förenta staterna, 84107
        • Intermountain Health - Salt Lake City
    • Virginia
      • Richmond, Virginia, Förenta staterna, 23225
        • HCA Chippenham
    • West Virginia
      • Charleston, West Virginia, Förenta staterna, 25304
        • CAMC
    • Wisconsin
      • Milwaukee, Wisconsin, Förenta staterna, 53215
        • Advocate Aurora St. Luke's
      • Bad Krozingen, Tyskland, 79189
        • Universitäts-Herzzentrum Freiburg
      • Berlin, Tyskland, 12683
        • UKB Berlin
      • Dresden, Tyskland, 01307
        • Herzzentrum Dresden

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Clinical Inclusion Criteria

Subjects must meet all of the following clinical criteria to participate in the trial:

  1. Subject is ≥ 18 years (or the minimum legal age as required by local regulations).
  2. Female subjects of childbearing potential must have a negative pregnancy test ≤ 7 days before the procedure or are using a contraceptive device or drug.
  3. Subject presents with chronic coronary syndromes [CCS] (manifest as documented angina or positive functional testing), unstable angina or stabilized non-ST elevation myocardial infarction (NSTEMI) (biomarkers stabilized or down trending) with an indication for PCI and planned intervention.
  4. Subject can tolerate dual antiplatelet therapy with aspirin, plus either Clopidogrel, Prasugrel, or Ticagrelor. (Note: For subjects requiring oral anticoagulation, aspirin may be omitted based on investigator discretion).
  5. Subject has life expectancy > 1 year in the opinion of the investigator.
  6. Subject is willing and able to provide informed consent and comply with study procedures and required follow-up evaluations.

PK Sub- Study Inclusion Criteria:

Subjects must meet all of the main protocol inclusion criteria to participate in the PK sub-study. Subjects must also meet the following additional PK sub-study inclusion criteria:

1. Subject is willing and able to provide informed consent for the PK sub-study and comply with the PK sub-study procedures and required follow-up evaluations.

Imaging Inclusion Criteria

Subject's target lesion(s) must meet all of the following angiographic criteria for the subject to participate in the trial:

  1. A single, target lesions that meet criteria can be treated in a single vessel. No non-target lesions can be treated within the target vessel in the index procedure. Non-target lesions within the target vessel can be staged for treatment > 30 days from the index procedure.
  2. Up to two (2) non-target lesions in up to two (2) non-target vessels may be treated, but successful PCI of the non-target lesions must be completed before randomization and treatment of the target lesion.
  3. Target lesion is ≤ 36 mm in length.
  4. Target lesion has diameter stenosis > 50% and ≤ 99% with distal flow at least thrombolysis in myocardial infarction (TIMI) 2.
  5. Target vessel has RVD of ≥ 2.00 mm and ≤ 2.75 mm [by visual assessment].
  6. Target lesion is within a native coronary artery or major branch.
  7. A target lesion within a bifurcation is allowed only if a single vessel (either main vessel or side branch) is to be treated.
  8. The identified target lesion has high probability for successful treatment with approved pre-treatment techniques and DEB alone based on Investigator assessment.

Exclusion Criteria:

  • Clinical Exclusion Criteria

Subjects who meet any of the following clinical criteria will be excluded from the trial:

  1. Subject with known hypersensitivity or allergy to Sirolimus or its analogues.
  2. Subject presents with NSTEMI and rising biomarkers, or ongoing chest pain or is hemodynamically instable.
  3. Subject with history of ST-elevation myocardial infarction (STEMI) within 30 days of the index procedure.
  4. Subject with planned major surgery within 30 days following the index procedure.
  5. Subject with planned treatment of lesion involving aorto-ostial location.
  6. Subject with PCI of a non-target vessel within ± 30 days of the index procedure.
  7. Subject with history (within 6 months prior to index procedure) of New York Heart Association (NYHA) class III or IV heart failure.
  8. Subject with history of active peptic ulcer or gastrointestinal bleeding within 6 months of the index procedure or other inability to comply with the recommended duration of dual antiplatelet therapy (DAPT).
  9. Subject is pregnant, breast-feeding or a woman of childbearing potential who plans pregnancy up to 1 year following index procedure.
  10. Subjects with current documented left ventricular ejection fraction (LVEF) < 30%.
  11. Subject is considered not able to tolerate at least 30 seconds of coronary occlusion for the target lesion treated.
  12. Subjects is currently participating in another investigational drug or device study that has not completed primary endpoint follow-up.
  13. Subject with definite clinically active COVID-19 infection defined as a positive COVID test within 24 hours of index procedure.
  14. Subject has chronic renal insufficiency (dialysis dependent, or glomerular filtration rate [GFR] ≤ 30 ml/min/1.73 m2 within 30 days of index procedure) or had undergone renal transplantation.

PK Sub-Study Exclusion Criteria:

Subjects must meet none of the main protocol exclusion criteria to participate in the PK sub-study. Subjects will be excluded if any of the following additional PK sub-study exclusion criteria are met:

  1. Any limus family (Zotarolimus, Everolimus, Sirolimus etc.) eluting device has been placed/used in any part of the body within 3 months prior to the index procedure including non-target lesion(s) treated during the index procedure.

  2. Planned intervention with any limus family (Zotarolimus, Everolimus, Sirolimus etc.) eluting device anywhere in the body within 6 months after the index procedure. Note: staged procedures >30 days after index procedure (Exclusion #6 of the main protocol) are permitted only in the main protocol, and are not permitted in this PK sub-study.

  3. The subject is taking or has taken within the last 3 months any limus family medication(s) for any reason.

  4. Subject is concurrently enrolled in the main protocol angiographic registry.

  5. Subjects who are taking strong CYP3A4 Inhibitors within 14 days before the index procedure or plan to take the strong inhibitors during the study period. Strong inhibitors include: cobicistat; ritonavir; indinavir and ritonavir; itraconazole; ketoconazole; lopinavir and ritonavir; paritaprevir and ritonavir and ombitasvir (and/or dasabuvir); posaconazole; saquinavir and ritonavir; tipranavir and ritonavir; elvitegravir and ritonavir; telithromycin; voriconazole; ceritinib; clarithromycin; idealalisib; nefazodone; nelfinavir.

  6. Subjects who are taking strong CYP3A4 Inducers within 14 days before the index procedure or plan to take the strong inducers during the study period. Strong inducers include apalutamide; carbamazepine; enzalutamide; ivosidenib; lumacaftor and ivacaftor; mitotane; phenytoin; rifampin; St. John's wort.

    • Angiographic Exclusion Criteria

Subject whose target lesion(s) meet any of the following angiographic criteria will be excluded from the trial:

  1. Target lesion is totally occluded or has evidence of thrombus.
  2. Target lesion is located in the left main or any arterial or venous graft.
  3. Target lesion is in a side branch that is "jailed" by a main vessel stent.
  4. In stent restenosis

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: SELUTION SLR 014 PTCA DEB

SELUTION Sustained Limus Release (SLR) 014 Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon (DEB)

The SELUTION SLR 014 PTCA DEB is a minimally invasive, single use and sterile Sirolimus coated PTCA balloon catheter.

The SELUTION SLR 014 PTCA DEB is available with balloon diameters from 2.0 to 3.0 mm and lengths of 15 to 40 mm for the purpose of the De Novo IDE trial

After target lesion pre-dilatation and preparation , a SELUTION SLR 014 PTCA DEB study device should be selected with nominal diameter equal to the RVD of the target lesion (1:1 ratio) and length that allows approximately 2.00 mm longer than the proximal and distal edges of the target lesion (defined as the proximal and distal extent of predilation). If IVUS is performed to assess RVD, and DEB upsizing is deemed clinically necessary for optimal results, a maximum nominal DEB diameter of 3.0 mm is permitted. The SELUTION SLR 014 PTCA DEB should then be delivered, positioned in and deployed per instructions per use. The balloon should be inflated for 60 seconds provided that the patient can tolerate this duration. The minimum inflation time is 30 seconds.

Aktiv komparator: Control Treatment

any FDA approved "limus-based" Drug Eluting Stent, as per standard institutional practice

For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.

The DES should be sized per IFU with respect to the vessel RVD. The use of IVUS or OCT is encouraged to guide optimal stent placement and assess final results. After DES deployment, additional balloon inflations should be performed as needed to obtain < 30% residual diameter stenosis and resolve proximal or distal edge dissections greater than or equal to NHLBI grade B.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Target lesion failure (TLF)
Tidsram: 12 months

Target lesion failure (TLF) is defined as the composite of cardiac death, target-vessel myocardial infarction (MI) or clinically-driven target lesion revascularization (TLR) at 12 months.

MI includes spontaneous (Type 1) MI using the 4th Universal Definition of Myocardial Infarction (UDMI) and peri-procedural MI using the Society for Cardiac Angiography and Intervention (SCAI) definition.

12 months
PK Sub-study Primary Endpoint 1
Tidsram: 6 months

PK parameters of C(max)

6 months
PK Sub-study Primary Endpoint 2
Tidsram: 6 months

PK parameters of T(max)

6 months
PK Sub-study Primary Endpoint 3
Tidsram: 6 months

PK parameters of AUC(last)

6 months
PK Sub-study Primary Endpoint 4
Tidsram: 6 months

PK parameters of MRT(last)

6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Secondary Endpoint 1
Tidsram: 12 months

Composite of all-cause mortality, target vessel MI or clinically driven target lesion revascularization

12 months
Secondary Endpoint 2
Tidsram: Up to 7 days

Lesion success, defined as attainment of < 30% residual stenosis of target lesion using any percutaneous method

Up to 7 days
Secondary Endpoint 3
Tidsram: Up to 7 days

Procedure success, defined as attainment of < 30% residual stenosis of the target lesion using the assigned study device only without the occurrence of in-hospital major adverse cardiac events (MACE), composite of all-cause death, MI or any clinically-driven TLR.

Up to 7 days
Secondary Endpoint 4
Tidsram: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Composite safety endpoint, defined as the patient-oriented composite of any death, any MI (spontaneous or peri-procedural), or any repeat revascularization.

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 5
Tidsram: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

All-Cause Mortality

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 6
Tidsram: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Cardiovascular Mortality

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 7
Tidsram: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

MI (spontaneous MI using the 4th UDMI, peri-procedural MI using SCAI and Academic Research Consortium [ARC]-2 definitions)

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 8
Tidsram: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Clinically-driven TLR

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 9
Tidsram: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

all TLR

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 10
Tidsram: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Clinically-driven Target Vessel Revascularization (TVR)

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 11
Tidsram: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

all TVR

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 12
Tidsram: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Non-target lesion revascularization

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 13
Tidsram: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

TLF

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 14
Tidsram: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Target vessel failure (TVF), defined as a composite of: cardiac death, target vessel MI (spontaneous or peri-procedural) and any clinically-driven TVR

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 15
Tidsram: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Stent or target lesion segment thrombosis (definite or probable) according to the ARC criteria for acute, subacute, late, very late and cumulative stent thrombosis

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years
Secondary Endpoint 16
Tidsram: 12 months

Bleeding Academic Research Consortium (BARC) class 2-5

12 months
Secondary Endpoint 17
Tidsram: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Net adverse clinical events, defined as death, MI (spontaneous or peri-procedural), TVR, stent/target lesion segment thrombosis or bleeding (BARC types 2-5, assessed to 12 months)

Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
PK Sub-Study Secondary Endpoint 1
Tidsram: 6 months

If calculations are valid, additional PK parameter of AUC(inf).

6 months
PK Sub-Study Secondary Endpoint 2
Tidsram: 6 months

If calculations are valid, additional PK parameter of Cl.

6 months
PK Sub-Study Secondary Endpoint 3
Tidsram: 6 months

If calculations are valid, additional PK parameter of Vz.

6 months
PK Sub-Study Secondary Endpoint 4
Tidsram: 6 months

If calculations are valid, additional PK parameter of Vss.

6 months
PK Sub-Study Secondary Endpoint 5
Tidsram: 6 months

If calculations are valid, additional PK parameter of half-life.

6 months
PK Sub-Study Secondary Endpoint 6
Tidsram: 6 months

Dose normalized C(max) will be considered if appropriate.

6 months
PK Sub-Study Secondary Endpoint 7
Tidsram: 6 months

Dose normalized AUC will be considered if appropriate.

6 months
PK Sub-Study Secondary Endpoint 8
Tidsram: 6 months

Device success, defined as attainment of ≤ 30% residual stenosis of the target lesion using the assigned device only

6 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Ron Waksman, MD, Medstar Health Research Institute

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

20 oktober 2023

Primärt slutförande (Beräknad)

1 september 2027

Avslutad studie (Beräknad)

1 september 2031

Studieregistreringsdatum

Först inskickad

30 juni 2023

Först inskickad som uppfyllde QC-kriterierna

7 juli 2023

Första postat (Faktisk)

14 juli 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

24 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

21 september 2026

Senast verifierad

1 september 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera